Patrick Baeuerle

iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany.

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA.

Part of Amgen, Inc., Amgen Research (Munich) GmbH is a biotechnology company based in Munich, Germany. The company has over 850 employees working at two locations in Germany. Amgen Scholars Europe Programs offer practical research experience to 100 students from all over Europe every summer. The company utilizes biotechnological possibilities to develop innovative treatments for diseases. The company continuously develops new substances to provide biopharmaceuticals to patients worldwide with serious illnesses. The CEOs of the company are Peter Kufer and Robert Saller. Amgen Research (Munich was acquired by ECKA Granulate GmbH & Co. KG from Aurubis AG on June 13, 2002.

Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer.